PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Aug 2020 16:49

RNS Number : 4200V
Horizon Discovery Group plc
06 August 2020
 

Horizon Discovery Group plc

 

TR-1: Standard form for notification of major holdings

 

 

Cambridge, UK, 6 August 2020: Horizon Discovery (LSE: HZD) ("Horizon", "the Group" or "the Company") announces that it has received the below TR1 form from ValueAct Capital Management, L.P. ("ValueAct") relating to the transfer of the management of the ValueAct Spring Master Fund, L.P. (the "Spring Master Fund") to Inclusive Capital Partners, L.P. ("Inclusive Capital") (the "Transfer"). The Transfer has been undertaken in relation to the Spring Master Fund's founder, Jeff Ubben, retiring from ValueAct and launching Inclusive Capital as announced in June 2020 and with effect from 31 July 2020. The full TR1 form from ValueAct is set out below.

 

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Horizon Discovery Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

ValueAct Capital Management, L.P.

City and country of registered office (if applicable)

San Francisco, United States of America

4. Full name of shareholder(s) (if different from 3.)v

Name

See Item 11

City and country of registered office (if applicable)

San Francisco, United States of America

5. Date on which the threshold was crossed or reachedvi:

31 July 2020

6. Date on which issuer notified (DD/MM/YYYY):

4 August 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0%

0%

157,976,096

Position of previous notification (if

applicable)

20.8%

20.8%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

0

0%

SUBTOTAL 8. A

0

0%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

VA Partners I, LLC

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

VA Partners I, LLC no longer serves as the General Partner (the "GP Change") of Inclusive Capital Partners Spring Master Fund, L.P. (f/k/a/ ValueAct Spring Master Fund, L.P.) ("Spring Fund"). ValueAct Capital Management, L.P. no longer renders management services to Spring Fund (the "Management Termination"). As a result of the GP Change and Management Termination, each of VA Partners I, LLC, ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, the General Partner to ValueAct Capital Management, L.P., ValueAct Holdings, L.P., the majority owner of the membership interests of VA Partners I, ValueAct Holdings II, L.P., the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC, and ValueAct Holdings GP, LLC, the General Partner to ValueAct Holdings, L.P. and ValueAct Holdings II, L.P., no longer holds any interest in securities of the Issuer.

 

Place of completion

San Francisco, United States of America

Date of completion

4 August 2020

 

 

Ends

 

 

For further information from Horizon Discovery Group plc, please contact:

 

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580

 

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

 

Consilium Strategic Communications (Financial Media and UK Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

 

Zyme Communications (Trade and Regional Media)

Lorna Cuddon

T Tel: +44 (0) 7811 996 942

Email: Lorna.cuddon@zymecommunications.com 

 

Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. +1 646-277-1282

Email: horizondiscovery@icrinc.com

 

About Horizon Discovery Group plc www.horizondiscovery.com

 

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a cell engineering company focused on commercializing the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development. Horizon's portfolio of tools and services is built on decades of experience in altering the expression of genes across mammalian and human cell types to provide cell engineering tools and services to customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Horizon's offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine. Horizon's customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organizations and academic researchers across the globe.

 

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

 

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUNSVRRUUWRAR
Date   Source Headline
16th Jan 20177:00 amRNSHorizon broadens gene editing capabilities
13th Jan 20177:00 amRNSAdditional Listing
6th Jan 20171:24 pmRNSAdditional Listing
29th Dec 201610:28 amRNSHolding(s) in Company
15th Dec 20167:00 amRNSAdditional Listing
2nd Dec 201611:30 amRNSDirector/PDMR Shareholding
2nd Dec 201610:00 amRNSDirector Dealings
16th Nov 20167:00 amRNSHZD Enters Chinese Clinical Diagnostics Market
14th Nov 20167:00 amRNSAdditional Listing
9th Nov 20167:00 amRNSOEM Agreement with CareDx for Reference Standards
1st Nov 20167:00 amRNSProgress Update: Molecular Screening Platform
31st Oct 201612:36 pmRNSAdditional Listing
19th Oct 20167:00 amRNSLicensing Agreement: Biomanufacturing Cell Lines
10th Oct 20167:00 amRNSAdditional Listing
30th Sep 20163:25 pmRNSHolding(s) in Company
30th Sep 20167:00 amRNSAdditional Listing
23rd Sep 20161:46 pmRNSHolding(s) in Company
21st Sep 20165:28 pmRNSHolding(s) in Company
20th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
13th Sep 20169:04 amRNSHolding(s) in Company
13th Sep 20167:00 amRNSBiomanufacturing Cell Lines Licensed to CPI, NIBRT
12th Sep 201611:04 amRNSHolding(s) in Company
7th Sep 201612:19 pmRNSHolding(s) in Company
7th Sep 20167:02 amRNSNotice of Interim Results
7th Sep 20167:00 amRNSAdditional Listing
6th Sep 201612:31 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSCRISPR Collaboration with Fulcrum Therapeutics
1st Sep 20167:00 amRNSHZD and Ventana Sign Reference Standards Agreement
18th Aug 20167:00 amRNSAdditional Listing
16th Aug 20164:09 pmRNSHolding(s) in Company
3rd Aug 20163:26 pmRNSHolding(s) in Company
29th Jul 20163:31 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHorizon Discovery Group Issue of Equity
26th Jul 201610:47 amRNSAdditional Listing
21st Jul 20169:11 amRNSAdditional Listing
13th Jul 20161:20 pmRNSHoldings in Company
7th Jul 20169:17 amRNSHoldings in Company
4th Jul 20164:33 pmRNSHoldings in Company
29th Jun 20164:01 pmRNSAdditional Listing
28th Jun 20167:00 amRNSAdditional Listing
24th Jun 201611:20 amRNSResult of AGM
9th Jun 20162:21 pmRNSGrant of Options
7th Jun 20165:19 pmRNSAnnual Report and Notice of Annual General Meeting
3rd Jun 20167:00 amRNSAdditional Listing
1st Jun 20167:00 amRNSReference Standards used in QIAGEN NGS System
12th May 20167:00 amRNSOEM Agreements with Market Leading NGS Company
11th May 20167:00 amRNSAdditional Listing
28th Apr 20167:45 amRNSAdditional Listing
26th Apr 20167:35 amRNSPreliminary Results for the Year Ended 31 Dec 2015
19th Apr 20167:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.